- Home
- IMCR
as 07-26-2024 4:00pm EST
Immunocore Holdings PLC is a late-stage biotechnology company engaged in the development of a novel class of TCR bispecific immunotherapies for the treatment of cancer, infectious and autoimmune diseases. Its geographical segments are the United Kingdom and the United States, of which the majority of its revenue comes from the United States.
| Founded: | 2008 | Country: | United Kingdom |
| Employees: | N/A | City: | OXFORDSHIRE |
| Market Cap: | 2.0B | IPO Year: | 2021 |
| Target Price: | $82.75 | AVG Volume (30 days): | 392.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 13 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.54 | EPS Growth: | N/A |
| 52 Week Low/High: | $33.05 - $76.98 | Next Earning Date: | 08-08-2024 |
| Revenue: | $264,253,750 | Revenue Growth: | 31.52% |
| Revenue Growth (this year): | 22.87% | Revenue Growth (next year): | 9.08% |
Stock Insider Trading Activity of Immunocore Holdings plc (IMCR)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| St Leger Tina Amber | IMCR | CHIEF HR OFFICER | Apr 1 '24 | Sell | $64.06 | 4,375 | $280,262.50 | 0 | SEC Form 4 |
| Berman David M | IMCR | HEAD OF R&D | Feb 28 '24 | Sell | $67.61 | 16,900 | $1,142,609.00 | 19,609 | SEC Form 4 |
| Berman David M | IMCR | HEAD OF R&D | Feb 28 '24 | Sell | $68.84 | 7,472 | $514,372.48 | 12,137 | SEC Form 4 |
| Berman David M | IMCR | HEAD OF R&D | Feb 28 '24 | Sell | $69.73 | 10,937 | $762,637.01 | 1,200 | SEC Form 4 |
| Berman David M | IMCR | HEAD OF R&D | Feb 28 '24 | Sell | $70.45 | 1,200 | $84,540.00 | 0 | SEC Form 4 |
| Berman David M | IMCR | HEAD OF R&D | Feb 26 '24 | Sell | $70.60 | 26,516 | $1,872,029.60 | 2,037 | SEC Form 4 |
| Berman David M | IMCR | HEAD OF R&D | Feb 26 '24 | Sell | $71.31 | 2,037 | $145,258.47 | 0 | SEC Form 4 |
| Berman David M | IMCR | HEAD OF R&D | Feb 26 '24 | Sell | $69.45 | 4,448 | $308,913.60 | 50,490 | SEC Form 4 |
| Berman David M | IMCR | HEAD OF R&D | Feb 26 '24 | Sell | $70.42 | 21,152 | $1,489,523.84 | 29,338 | SEC Form 4 |
| Berman David M | IMCR | HEAD OF R&D | Feb 26 '24 | Sell | $71.32 | 25,944 | $1,850,326.08 | 3,394 | SEC Form 4 |
| Berman David M | IMCR | HEAD OF R&D | Feb 26 '24 | Sell | $71.97 | 3,394 | $244,266.18 | 0 | SEC Form 4 |
| St Leger Tina Amber | IMCR | Chief HR Officer | Jan 3 '24 | Sell | $69.85 | 4,068 | $284,149.80 | 307 | SEC Form 4 |
| St Leger Tina Amber | IMCR | Chief HR Officer | Jan 3 '24 | Sell | $70.46 | 307 | $21,631.22 | 0 | SEC Form 4 |
Latest Immunocore Holdings plc News
IMCR Breaking Stock News: Dive into IMCR Ticker-Specific Updates for Smart Investing
MT Newswires
a month ago
Immunocore Randomizes First Patient in Phase 3 Trial of Cutaneous Melanoma Combination Treatment
GlobeNewswire
a month ago
Immunocore announces randomization of first patient in the global, registrational Phase 3 clinical trial testing brenetafusp for the treatment of first-line advanced or metastatic cutaneous melanoma
Business Wire
2 months ago
Engelhart Commodities Trading Partners Agrees to Acquire Trailstone, Strengthening Commitment to the Energy Transition
GlobeNewswire
2 months ago
Delfi Meedia, a subsidiary of AS Ekspress Grupp to acquire business operations of Eesti Koolitus- ja Konverentsikeskus
GlobeNewswire
2 months ago
Share buy-back programme - week 23
Simply Wall St.
2 months ago
Do Scientex Berhad's (KLSE:SCIENTX) Earnings Warrant Your Attention?
Reuters
2 months ago
Japan's service sector mood hits nearly 2-year low in May
AFP
2 months ago
N. Korea sends more balloons as Kim's sister warns of 'new counteraction'
Compare IMCR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IMCR Immunocore Holdings plc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.